[Skip to Content]
[Skip to Content Landing]
Viewpoint
June 2018

Global Cancer Clinical Trials—Cooperation Between Investigators in High-Income Countries and Low- and Middle-Income Countries

Author Affiliations
  • 1Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai, India
  • 2Radiation Oncology, Tata Memorial Hospital, Parel, Mumbai, India
JAMA Oncol. 2018;4(6):765-766. doi:10.1001/jamaoncol.2017.5856

Globalization of cancer clinical trials over the past few decades has led to some successful collaboration between researchers from low- and middle-income countries (LMICs) and those from high income-countries (HICs), overcoming geographical and political boundaries. The HICs and the entire global scientific community stand to gain from such cooperation in terms of cost-effectiveness and timely completion of clinical trials, which translates to faster adoption of newer and novel treatments. The LMICs seemingly also benefit from improved infrastructure, reduced abandonment, trained human resources, better follow-up, and early access to novel technologies. The infrastructure built for clinical research can be used subsequently to provide improved clinical care in resource-poor settings.1

×